Every material Form 8-K Elevance Health filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Elevance Health reported third quarter 2024 operating revenue of $44.7 billion, up 5.3% from a year earlier, but GAAP diluted EPS fell 20.0% to $4.36 and the operating gain fell 19.8% to $1.4 billion. The company cited a timing mismatch between Medicaid rates and the higher acuity of its members, which pushed the benefit expense ratio up 270 basis points to 89.5%. It now expects 2024 GAAP EPS of approximately $26.50 and adjusted EPS of approximately $33.00, and on October 15, 2024 it authorized an $8.0 billion increase to its share repurchase program.
Q3 2024 operating revenue $44.7 billion, up $2.2 billion from the prior year quarter, driven by higher premium yields and CarelonRx product revenue
Q3 2024 GAAP diluted EPS $4.36 versus $5.45 a year earlier; adjusted diluted EPS $8.37 versus $8.99
Medical membership fell 3.3% year over year to 45,760 thousand, with Medicaid down 19.0% to 8,926 thousand
Board authorized an $8.0 billion increase to the share repurchase program on October 15, 2024; quarterly dividend of $1.63 per share declared
Elevance Health reported second quarter 2024 results, with GAAP diluted EPS of $9.85, up 26%, and adjusted diluted EPS of $10.12, up 12%. Operating revenue slipped to $43.2 billion from $43.4 billion, while the company said it has prudently maintained its full-year outlook of at least $37.20 in adjusted EPS.
Q2 2024 operating revenue was $43.2 billion, down $0.2 billion from the prior year quarter, driven by Medicaid membership attrition
GAAP diluted EPS was $9.85 versus $7.79 a year earlier; adjusted diluted EPS was $10.12 versus $9.04
Full-year 2024 outlook: GAAP diluted EPS of at least $34.05 and adjusted diluted EPS of at least $37.20
Board declared a third quarter dividend of $1.63 per share, payable September 25, 2024, to holders of record on September 10, 2024
Elevance Health reported first quarter 2024 results on April 18, 2024, with operating revenue of $42.3 billion, up 0.9% from a year earlier, and diluted EPS of $9.59, up 15.5%. The company raised its full-year 2024 guidance to diluted EPS greater than $34.05 and adjusted diluted EPS greater than $37.20, which signals stronger expected earnings for shareholders.
Q1 2024 diluted EPS was $9.59, up 15.5%; adjusted diluted EPS was $10.64, up 12.5%
Operating revenue was $42.3 billion, up 0.9%; total operating margin was 7.1%, up 30 basis points
Full-year 2024 diluted EPS guidance raised to greater than $34.05; adjusted diluted EPS guidance raised to greater than $37.20
Repurchased 1.1 million shares for $566 million in Q1; quarterly dividend of $1.63 per share declared, payable June 25, 2024
Elevance Health reported fourth-quarter and full-year 2023 results in a press release furnished under Item 2.02 of this 8-K. Quarterly operating revenue rose 7.0% to $42.5 billion and GAAP diluted EPS rose 1.1% to $3.63, while the company set a full-year 2024 GAAP diluted EPS outlook of greater than $34.29, compared with $25.22 for 2023, and raised its quarterly dividend 10.1% to $1.63 per share.
4Q 2023 operating revenue $42.5 billion, up 7.0%; GAAP diluted EPS $3.63, up 1.1%; adjusted diluted EPS $5.62, up 15.2%
FY 2024 GAAP diluted EPS outlook greater than $34.29; adjusted diluted EPS outlook greater than $37.10, versus FY 2023 GAAP diluted EPS of $25.22
Quarterly dividend increased 10.1% to $1.63 per share
4Q 2023 operating margin was 3.0%, down from 3.2% in 4Q 2022
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Elevance Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →